TY - JOUR
TI - Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review
and Implications for Future Research
AU - Bikdeli, Behnood
AU - Madhavan, Mahesh V.
AU - Gupta, Aakriti
AU - Jimenez,
AU - David
AU - Burton, John R.
AU - Nigoghossian, Caroline Der
AU - Chuich,
AU - Taylor
AU - Nouri, Shayan Nabavi
AU - Dreyfus, Isaac
AU - Driggin, Elissa
AU - and Sethi, Sanjum
AU - Sehgal, Kartik
AU - Chatterjee, Saurav
AU - Ageno,
AU - Walter
AU - Madjid, Mohammad
AU - Guo, Yutao
AU - Tang, Liang V.
AU - Hu, Yu
AU - and Bertoletti, Laurent
AU - Giri, Jay
AU - Cushman, Mary
AU - Quere,
AU - Isabelle
AU - Dimakakos, Evangelos P.
AU - Gibson, C. Michael
AU - Lippi,
AU - Giuseppe
AU - Favaloro, Emmanuel J.
AU - Fareed, Jawed
AU - Tafur, Alfonso
AU - J.
AU - Francese, Dominic P.
AU - Batra, Jaya
AU - Falanga, Anna and
AU - Clerkin, Kevin J.
AU - Uriel, Nir
AU - Kirtane, Ajay
AU - McLintock, Claire
AU - and Hunt, Beverley J.
AU - Spyropoulos, Alex C.
AU - Barnes, Geoffrey D.
AU - and Eikelboom, John W.
AU - Weinberg, Ido
AU - Schulman, Sam
AU - Carrier,
AU - Marc
AU - Piazza, Gregory
AU - Beckman, Joshua A.
AU - Leon, Martin B. and
AU - Stone, Gregg W.
AU - Rosenkranz, Stephan
AU - Goldhaber, Samuel Z. and
AU - Parikh, Sahil A.
AU - Monreal, Manuel
AU - Krumholz, Harlan M. and
AU - Konstantinides, Stavros V.
AU - Weitz, Jeffrey I.
AU - Lip, Gregory Y. H.
AU - and Global COVID-19 Thrombosis Collabo
JO - Thrombosis and Haemostasis
PY - 2020
VL - 120
TODO - 07
SP - 1004-1024
PB - Georg Thieme Verlag KG
SN - 0340-6245
TODO - 10.1055/s-0040-1713152
TODO - coronavirus disease 2019; thrombosis; inflammation; fibrinolytic
therapy; anticoagulation; immunomodulator; antithrombin; thrombomodulin
TODO - Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is
a viral illness caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic
events to morbidity and mortality in COVID-19 patients has prompted a
search for novel potential options for preventing COVID-19-associated
thrombotic disease. In this article by the Global COVID-19 Thrombosis
Collaborative Group, we describe novel dosing approaches for commonly
used antithrombotic agents (especially heparin-based regimens) and the
potential use of less widely used antithrombotic drugs in the absence of
confirmed thrombosis. Although these therapies may have direct
antithrombotic effects, other mechanisms of action, including
anti-inflammatory or antiviral effects, have been postulated. Based on
survey results from this group of authors, we suggest research
priorities for specific agents and subgroups of patients with COVID-19.
Further, we review other agents, including immunomodulators, that may
have antithrombotic properties. It is our hope that the present document
will encourage and stimulate future prospective studies and randomized
trials to study the safety, efficacy, and optimal use of these agents
for prevention or management of thrombosis in COVID-19.
ER -